| Literature DB >> 33122810 |
Tobi F Somerville1,2, Jayendra Shankar3, Sarah Aldwinckle3, Henri Sueke4,3, Timothy Neal5, Malcolm J Horsburgh6, Stephen B Kaye4,3.
Abstract
This study investigated Staphylococcus aureus carriage in patients with microbial keratitis (MK). 215 patients with MK, 60 healthy controls and 35 patients with rheumatoid arthritis (RA) were included. Corneal scrapes were collected from patients with MK. Conjunctival, nasal and throat swabs were collected from the non-MK groups on a single occasion and from the MK group at presentation and then at 6 and 12 weeks. Samples were processed using conventional diagnostic culture. 68 (31.6%) episodes of clinically suspected MK were classed as recurrent. Patients with recurrent MK had a higher isolation rate of S. aureus from their cornea than those with a single episode (p < 0.01) and a higher isolation rate of S. aureus from their conjunctiva compared to control participants, 20.6% (14/68) versus 3% (5/60) respectively (p = 0.01). Significantly more patients with recurrent MK (12/68, 17.6%) were found to have S. aureus isolated from both their conjunctiva and nose than those with a single episode of MK (7/147, 4.8% p = 0.002) and compared to patients in the control group (3/60, 5.0% p = 0.03). The results indicate that patients with recurrent MK have higher rates of carriage of S. aureus suggesting endogenous site colonisation as a possible source of recurrent infection.Entities:
Mesh:
Year: 2020 PMID: 33122810 PMCID: PMC7596706 DOI: 10.1038/s41598-020-75821-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline demographics and predisposing risk factors of patients with clinically suspected MK.
| Single episode MK (n = 147) | Recurrent MK (n = 68) | P-value | |
|---|---|---|---|
| Age (median, IQR) | 48 years (30.5) | 54 years (19.3) | 0.21 |
| Males | 79 (53.7%) | 30 (44.1%) | 0.19 |
| Diabetes mellitus | 10 (6.8%) | 6 (8.8%) | 0.60 |
| Rheumatoid arthritis | 6 (4.1%) | 16 (23.5%) | < 0.01* |
| Sjogren’s syndrome | 1 (0.7%) | 6 (8.8%) | 0.004* |
| Ectodermal dysplasia | 0 | 4 (5.9%) | 0.009* |
| Systemic immunosuppression | 5 (3.4%) | 13 (19.1%) | < 0.001* |
| Contact lens wear | 61 (42.5%) | 7 (10.3%) | < 0.001* |
| Ocular surface disease | 64 (43.5%) | 46 (67.6%) | 0.001* |
| Corneal trauma | 20 (13.6%) | 2 (2.9%) | 0.02 |
| Topical steroid prior to presentation | 12 (8.2%) | 12 (17.6%) | 0.06 |
MK microbial keratitis.
*Significant after Bonferroni correction.
Isolates from cases of presumed microbial keratitis grouped according to patients with recurrent episodes and those presenting with only a single episode.
| Single episode MK (n = 146) | Recurrent MK (n = 58) | |
|---|---|---|
| 39* (26.7%) | 13* (22.4%) | |
| 19 (13.0%) | 10 (17.2%) | |
| 2 (1.4%) | 5 (8.6%) | |
| CNS | 11 (7.5%) | 3 (5.2%) |
| 4 (2.7%) | 2 (3.4%) | |
| 2 (1.4%) | 1 (1.7%) | |
| 1 (0.7%) | 1 (1.7%) | |
| 0 | 1 (1.7%) | |
| Diptheroids | 1 (0.7%) | 0 |
| 19 (13.0%) | 3 (5.2%) | |
| 9 (6.1%) | 1 (1.7%) | |
| 4 (2.7%) | 0 | |
| 1 (0.7%) | 0 | |
| 0 | 1 (1.7%) | |
| 1 (0.7%) | 0 | |
| 1 (0.7%) | 0 | |
| 1 (0.7%) | 0 | |
| 1 (0.7%) | 1 (1.7%) | |
| Other Enterobacteriaceae sp. | 1 (0.7%) | 0 |
| 1 (0.7%) | 0 | |
| A | 1 (0.7%) | 0 |
| 1 (0.7%) | 0 | |
| 1 (0.7%) | 0 |
*The total number of isolates do not add up to 39 and 13 respectively because one recurrent patient had mixed infection with S. aureus, E.coli and S. pneumoniae and two single episode patients had mixed infection with Enterobacteriaeceae and Alpha-Haemolytic Streptococci, and Pseudomonas aeruginosa and Aspergillus sp, respectively.
MK microbial keratitis, CNS coagulase-negative Staphylococci.
Numbers of individuals in each group who had S. aureus isolated from their conjunctiva, nose and throat on presentation.
| Control (n = 60) | Single episode MK (n = 147) | Recurrent MK (n = 68) | MK with positive scrape (n = 52) | ||||
|---|---|---|---|---|---|---|---|
| Conjunctiva | 3 (5.0%) | 9 (6.1%) | P = 1.00 | 6 (11.5%) | P = 0.30 | ||
| Nose | 18 (30.0%) | 47 (32.0%) | P = 0.66 | 29 (42.6%) | P = 0.12 | 17 (32.7%) | P = 0.66 |
| Throat | 4 (6.8%) | 19 (12.9%) | P = 0.33 | 10 (14.7%) | P = 0.26 | 9 (17.3%) | P = 0.14 |
P-values represent comparisons of each group to the control group.
MK microbial keratitis.
Microbial keratitis participants overall S. aureus carriage (total S. aureus conjunctival, nasal and throat carriage) at presentation (visit 1), 6 weeks post presentation (visit 2) and 12 weeks post presentation (visit 3).
| Single episode MK | Recurrent MK | MK positive scrape episodes | ||
|---|---|---|---|---|
| Visit 1 | 75/441 (17.0%) | 53/204 (26.0%) | 32/156 (20.5%) | 6/21 (28.6%) |
| Visit 2 | 47/303 (15.5%) | 26/168 (15.5%) | 26/117 (22.2%) | 5/18 (27.8%) |
| Visit 3 | 40/237 (16.9%) | 26/141 (18.4%) | 17/96 (17.7%) | 4/12 (33.3%) |
| P value | 0.85 | 0.04 | 0.72 | 0.94 |
Values represent the total number of swabs obtained (nasal swabs were classified as one value and counted as positive regardless if one or both nares were positive). P-values calculated using repeated measures logistic regression (Wald Chi-Square) and represent change over time in S. aureus colonization prevalence for each of the four subject groups.
MK microbial keratitis.
Numbers of individuals in the healthy control group versus patients with RA on systemic immunotherapy and patients with RA not on systemic immunotherapy who had S. aureus isolated from their conjunctiva, nose and throat.
| Healthy controls (n = 60) | Patients with RA on systemic immunotherapy (n = 29) | Patients with RA not on systemic immunotherapy (n = 6) | Difference between RA groups | |||
|---|---|---|---|---|---|---|
| Conjunctiva | 3 (5.0%) | 0 | P = 0.55a | 0 | P = 1.00b | – |
| Nose | 18 (30.0%) | 13 (44.8%) | P = 0.17a | 0 | P = 0.18b | P = 0.06 |
| Throat | 4 (6.8%) | 3 (10.3%) | P = 0.68a | 0 | P = 1.00b | P = 1.00 |
aP-values represent comparison between patients with RA on systemic immunotherapy and healthy controls.
bP-values represent comparison between patients with RA not on systemic immunotherapy and healthy controls.
RA rheumatoid arthritis.